Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adriamycin and Cytoxan · 1 trial · 1 indication
Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 3 months after chemotherapy (month 7). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 3 months after chemotherapy (month 7).
Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of \>=20% in any treatment arm, and participants with at least one toxicity are reported. Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 6 months after chemotherapy (month 10). Entire regiments (AC --\> ABI-007 and AC --\> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 6 months after chemotherapy (month 10).
| Arm | Type | Description |
|---|---|---|
| AC --> ABI-007 | EXPERIMENTAL | Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m\^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46). |
| AC --> Taxol | EXPERIMENTAL | Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m\^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46). |
| Name | Type | Description |
|---|---|---|
| Adriamycin and Cytoxan (AC) | DRUG | Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8). |
| ABI-007 | DRUG | 260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16) |
| Taxol | DRUG | 175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16) |
| Bevacizumab | DRUG | 10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46). |
| pegfilgrastim | DRUG | 6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary. |
Inclusion Criteria: A patient was eligible for inclusion in this study only if all of the following criteria were met: 1. Female, age greater than or equal to 18 to less than or equal to 70 years old. 2. Estrogen receptor (ER) and progesterone receptor (PR) status have been determined. 3. Operable...
Top 20 of 92 competitors
Adriamycin and Cytoxan is a combination of two chemotherapy drugs used in the treatment of breast cancer. It is being studied as adjuvant therapy, meaning it is given after primary treatment to reduce the risk of cancer recurrence. The combination is administered in a dose-dense schedule as part of a clinical trial.
Adriamycin and Cytoxan is developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this combination for the treatment of breast cancer.
Adriamycin and Cytoxan is in Phase 2 clinical development for breast cancer. It is an investigational combination and is not yet approved by regulatory authorities. The Phase 2 trial has been completed, with results informing further development.
Adriamycin and Cytoxan was studied in a Phase 2 clinical trial with the identifier NCT00394251. This completed trial enrolled 197 female patients with breast cancer in the United States. The study evaluated dose-dense Adriamycin plus Cytoxan followed by either ABI-007 or Taxol with bevacizumab as adjuvant therapy.
Yes, Adriamycin and Cytoxan is commonly referred to as AC, which stands for the combination of Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide). This abbreviation is used in clinical settings and research to denote the two-drug regimen.